| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215;
Crucell Holland, Leiden, The Netherlands;
Therion Biologics, Cambridge, MA 02142; and
Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892
The high prevalence of pre-existing immunity to adenovirus serotype 5 (Ad5) in human populations may substantially limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for HIV-1 and other pathogens. A potential solution to this problem is to use vaccine vectors derived from adenovirus (Ad) serotypes that are rare in humans, such as Ad35. However, cross-reactive immune responses between heterologous Ad serotypes have been described and could prove a major limitation of this strategy. In particular, the extent of immunologic cross-reactivity between Ad5 and Ad35 has not previously been determined. In this study we investigate the impact of pre-existing anti-Ad5 immunity on the immunogenicity of candidate rAd5 and rAd35 vaccines expressing SIV Gag in mice. Anti-Ad5 immunity at levels typically found in humans dramatically blunted the immunogenicity of rAd5-Gag. In contrast, even high levels of anti-Ad5 immunity did not substantially suppress Gag-specific cellular immune responses elicited by rAd35-Gag. Low levels of cross-reactive Ad5/Ad35-specific CD4+ T lymphocyte responses were observed, but were insufficient to suppress vaccine immunogenicity. These data demonstrate the potential utility of Ad35 as a candidate vaccine vector that is minimally suppressed by anti-Ad5 immunity. Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity.
This article has been cited by other articles:
|
|
 |
|
  D. Safronetz, N. R. Hegde, H. Ebihara, M. Denton, G. P. Kobinger, S. St. Jeor, H. Feldmann, and D. C. Johnson Adenovirus Vectors Expressing Hantavirus Proteins Protect Hamsters against Lethal Challenge with Andes Virus J. Virol., July 15, 2009; 83(14): 7285 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Adams, E. Bond, M. J. E. Havenga, L. Holterman, J. Goudsmit, G. B. Karlsson Hedestam, R. A. Koup, and K. Lore Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN J. Gen. Virol., July 1, 2009; 90(7): 1600 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Klempa, D. H. Kruger, B. Auste, M. Stanko, A. Krawczyk, K. F. Nickel, K. Uberla, and A. Stang A Novel Cardiotropic Murine Adenovirus Representing a Distinct Species of Mastadenoviruses J. Virol., June 1, 2009; 83(11): 5749 - 5759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Geiben-Lynn, J. R. Greenland, K. Frimpong-Boateng, N. van Rooijen, A.-H. Hovav, and N. L. Letvin CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses Blood, December 1, 2008; 112(12): 4585 - 4590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Fang, J. Y. Wang, M. Chinchilla, M. M. Levine, W. C. Blackwelder, and J. E. Galen Use of mchI Encoding Immunity to the Antimicrobial Peptide Microcin H47 as a Plasmid Selection Marker in Attenuated Bacterial Live Vectors Infect. Immun., October 1, 2008; 76(10): 4422 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Kaufman, J. Liu, A. Carville, K. G. Mansfield, M. J. E. Havenga, J. Goudsmit, and D. H. Barouch Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination J. Immunol., September 15, 2008; 181(6): 4188 - 4198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Kaufman, J. Goudsmit, L. Holterman, B. A. Ewald, M. Denholtz, C. Devoy, A. Giri, L. E. Grandpre, J.-M. Heraud, G. Franchini, et al. Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice J. Virol., July 15, 2008; 82(14): 6829 - 6837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. C. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys J. Virol., May 15, 2008; 82(10): 4844 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yang, B. J. Whalen, R. S. Tirabassi, L. K. Selin, T. S. Levchenko, V. P. Torchilin, E. H. Kislauskis, and D. L. Guberski A DNA Vaccine Prime Followed by a Liposome-Encapsulated Protein Boost Confers Enhanced Mucosal Immune Responses and Protection J. Immunol., May 1, 2008; 180(9): 6159 - 6167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sridhar, A. Reyes-Sandoval, S. J. Draper, A. C. Moore, S. C. Gilbert, G. P. Gao, J. M. Wilson, and A. V. S. Hill Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A J. Virol., April 15, 2008; 82(8): 3822 - 3833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Schoenly and D. B. Weiner Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business" J. Virol., April 1, 2008; 82(7): 3166 - 3180. [Full Text] [PDF]
|
|
|
|
|
|
A. Rodriguez, J. Goudsmit, A. Companjen, R. Mintardjo, G. Gillissen, D. Tax, J. Sijtsma, G. J. Weverling, L. Holterman, D. E. Lanar, et al. Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 Infect. Immun., April 1, 2008; 76(4): 1709 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Geiben-Lynn, J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses Clin. Vaccine Immunol., April 1, 2008; 15(4): 691 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ljungberg, A. C. Whitmore, M. E. Fluet, T. P. Moran, R. S. Shabman, M. L. Collier, A. A. Kraus, J. M. Thompson, D. C. Montefiori, C. Beard, et al. Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine J. Virol., December 15, 2007; 81(24): 13412 - 13423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Worgall, A. Krause, J. Qiu, J. Joh, N. R. Hackett, and R. G. Crystal Protective Immunity to Pseudomonas aeruginosa Induced with a Capsid-Modified Adenovirus Expressing P. aeruginosa OprF J. Virol., December 15, 2007; 81(24): 13801 - 13808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stahl-Hennig, S. Kuate, M. Franz, Y. S. Suh, H. Stoiber, U. Sauermann, K. Tenner-Racz, S. Norley, K. S. Park, Y. C. Sung, et al. Atraumatic Oral Spray Immunization with Replication-Deficient Viral Vector Vaccines J. Virol., December 1, 2007; 81(23): 13180 - 13190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Boyer, T. M. Robinson, M. A. Kutzler, G. Vansant, D. A. Hokey, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, G. N. Pavlakis, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid PNAS, November 20, 2007; 104(47): 18648 - 18653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. White, M. M. Parsons, A. C. Whitmore, B. M. Williams, A. de Silva, and R. E. Johnston An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice J. Virol., October 1, 2007; 81(19): 10329 - 10339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Santra, Y. Sun, J. G. Parvani, V. Philippon, M. S. Wyand, K. Manson, A. Gomez-Yafal, G. Mazzara, D. Panicali, P. D. Markham, et al. Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors J. Virol., August 15, 2007; 81(16): 8563 - 8570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Radosevic, C. W. Wieland, A. Rodriguez, G. J. Weverling, R. Mintardjo, G. Gillissen, R. Vogels, Y. A. W. Skeiky, D. M. Hone, J. C. Sadoff, et al. Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon Infect. Immun., August 1, 2007; 75(8): 4105 - 4115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lore, W. C. Adams, M. Havenga, M. L. Precopio, L. Holterman, J. Goudsmit, and R. A. Koup Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses J. Immunol., August 1, 2007; 179(3): 1721 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Abbink, A. A. C. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D J. Virol., May 1, 2007; 81(9): 4654 - 4663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Greenland, R. Geiben, S. Ghosh, W. A. Pastor, and N. L. Letvin Plasmid DNA Vaccine-Elicited Cellular Immune Responses Limit In Vivo Vaccine Antigen Expression through Fas-Mediated Apoptosis J. Immunol., May 1, 2007; 178(9): 5652 - 5658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, B. A. Ewald, D. M. Lynch, A. Nanda, S. M. Sumida, and D. H. Barouch Modulation of DNA Vaccine-Elicited CD8+ T-Lymphocyte Epitope Immunodominance Hierarchies J. Virol., December 15, 2006; 80(24): 11991 - 11997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Thorner, A. A. C. Lemckert, J. Goudsmit, D. M. Lynch, B. A. Ewald, M. Denholtz, M. J. E. Havenga, and D. H. Barouch Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity J. Virol., December 15, 2006; 80(24): 12009 - 12016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Thorner, R. Vogels, J. Kaspers, G. J. Weverling, L. Holterman, A. A. C. Lemckert, A. Dilraj, L. M. McNally, P. M. Jeena, S. Jepsen, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-saharan Africa. J. Clin. Microbiol., October 1, 2006; 44(10): 3781 - 3783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. C. Lemckert, J. Grimbergen, S. Smits, E. Hartkoorn, L. Holterman, B. Berkhout, D. H. Barouch, R. Vogels, P. Quax, J. Goudsmit, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2891 - 2899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Leopold, R. L. Wendland, T. Vincent, and R. G. Crystal Neutralized Adenovirus-Immune Complexes Can Mediate Effective Gene Transfer via an Fc Receptor-Dependent Infection Pathway. J. Virol., October 1, 2006; 80(20): 10237 - 10247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Havenga, R. Vogels, D. Zuijdgeest, K. Radosevic, S. Mueller, M. Sieuwerts, F. Weichold, I. Damen, J. Kaspers, A. Lemckert, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol., August 1, 2006; 87(Pt 8): 2135 - 2143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Cayabyab, A.-H. Hovav, T. Hsu, G. R. Krivulka, M. A. Lifton, D. A. Gorgone, G. J. Fennelly, B. F. Haynes, W. R. Jacobs Jr., and N. L. Letvin Generation of CD8+ T-Cell Responses by a Recombinant Nonpathogenic Mycobacterium smegmatis Vaccine Vector Expressing Human Immunodeficiency Virus Type 1 Env J. Virol., February 15, 2006; 80(4): 1645 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Capone, A. Meola, B. B. Ercole, A. Vitelli, M. Pezzanera, L. Ruggeri, M. E. Davies, R. Tafi, C. Santini, A. Luzzago, et al. A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques J. Virol., February 15, 2006; 80(4): 1688 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verhaagh, E. de Jong, J. Goudsmit, S. Lecollinet, G. Gillissen, M. de Vries, K. van Leuven, I. Que, K. Ouwehand, R. Mintardjo, et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors J. Gen. Virol., February 1, 2006; 87(2): 255 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. A. E. Ophorst, K. Radosevic, M. J. E. Havenga, M. G. Pau, L. Holterman, B. Berkhout, J. Goudsmit, and M. Tsuji Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice Infect. Immun., January 1, 2006; 74(1): 313 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors J. Gen. Virol., January 1, 2006; 87(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-C. Yang, J. Millar, T. Groves, N. Grinshtein, R. Parsons, S. Takenaka, Y. Wan, and J. L. Bramson The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity J. Immunol., January 1, 2006; 176(1): 200 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. McDermott, D. H. O'Connor, S. Fuenger, S. Piaskowski, S. Martin, J. Loffredo, M. Reynolds, J. Reed, J. Furlott, T. Jacoby, et al. Cytotoxic T-Lymphocyte Escape Does Not Always Explain the Transient Control of Simian Immunodeficiency Virus SIVmac239 Viremia in Adenovirus-Boosted and DNA-Primed Mamu-A*01-Positive Rhesus Macaques J. Virol., December 15, 2005; 79(24): 15556 - 15566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nanda, D. M. Lynch, J. Goudsmit, A. A. C. Lemckert, B. A. Ewald, S. M. Sumida, D. M. Truitt, P. Abbink, M. G. Kishko, D. A. Gorgone, et al. Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys J. Virol., November 15, 2005; 79(22): 14161 - 14168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hashimoto, J. L. Boyer, N. R. Hackett, J. M. Wilson, and R. G. Crystal Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity Infect. Immun., October 1, 2005; 73(10): 6885 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Peng, L. R. Wang, V. R. Gomez-Roman, A. Davis-Warren, D. C. Montefiori, V. S. Kalyanaraman, D. Venzon, J. Zhao, E. Kan, T. J. Rowell, et al. Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies J. Virol., August 15, 2005; 79(16): 10200 - 10209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. C. Lemckert, S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Lifton, et al. Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity J. Virol., August 1, 2005; 79(15): 9694 - 9701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wu, W.-p. Kong, and G. J. Nabel Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens J. Virol., July 1, 2005; 79(13): 8024 - 8031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vellinga, S. Van der Heijdt, and R. C. Hoeben The adenovirus capsid: major progress in minor proteins J. Gen. Virol., June 1, 2005; 86(6): 1581 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, A. A. C. Lemckert, R. Vogels, J. H. H. V. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein J. Immunol., June 1, 2005; 174(11): 7179 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Santra, M. S. Seaman, L. Xu, D. H. Barouch, C. I. Lord, M. A. Lifton, D. A. Gorgone, K. R. Beaudry, K. Svehla, B. Welcher, et al. Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates J. Virol., May 15, 2005; 79(10): 6516 - 6522. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
